Your browser doesn't support javascript.
loading
Precise Control of Target Temperature Using N6-Cyclohexyladenosine and Real-Time Control of Surface Temperature.
Laughlin, Bernard W; Bailey, Isaac R; Rice, Sarah A; Barati, Zeinab; Bogren, Lori K; Drew, Kelly L.
Afiliação
  • Laughlin BW; 1 Institute of Arctic Biology, University of Alaska Fairbanks College of Natural Science and Mathematics , Fairbanks, Alaska.
  • Bailey IR; 2 Department of Chemistry and Biochemistry, University of Alaska Fairbanks College of Natural Science and Mathematics , Fairbanks, Alaska.
  • Rice SA; 1 Institute of Arctic Biology, University of Alaska Fairbanks College of Natural Science and Mathematics , Fairbanks, Alaska.
  • Barati Z; 2 Department of Chemistry and Biochemistry, University of Alaska Fairbanks College of Natural Science and Mathematics , Fairbanks, Alaska.
  • Bogren LK; 1 Institute of Arctic Biology, University of Alaska Fairbanks College of Natural Science and Mathematics , Fairbanks, Alaska.
  • Drew KL; 2 Department of Chemistry and Biochemistry, University of Alaska Fairbanks College of Natural Science and Mathematics , Fairbanks, Alaska.
Ther Hypothermia Temp Manag ; 8(2): 108-116, 2018 Jun.
Article em En | MEDLINE | ID: mdl-29480748
ABSTRACT
Targeted temperature management is standard of care for cardiac arrest and is in clinical trials for stroke. N6-cyclohexyladenosine (CHA), an A1 adenosine receptor (A1AR) agonist, inhibits thermogenesis and induces onset of hibernation in hibernating species. Despite promising thermolytic efficacy of CHA, prior work has failed to achieve and maintain a prescribed target core body temperature (Tb) between 32°C and 34°C for 24 hours. We instrumented Sprague-Dawley rats (n = 19) with indwelling arterial and venous cannulae and a transmitter for monitoring Tb and ECG, then administered CHA via continuous IV infusion or intraperitoneal (IP) injection. In the first experiment (n = 11), we modulated ambient temperature and increased the dose of CHA in an attempt to manage Tb. In the second experiment (n = 8), we administered CHA (0.25 mg/[kg·h]) via continuous IV infusion and modulated cage surface temperature to control Tb. We rewarmed animals by increasing surface temperature at 1°C h-1 and discontinued CHA after Tb reached 36.5°C. Tb, brain temperature (Tbrain), heart rate, blood gas, and electrolytes were also monitored. Results show that titrating dose to adjust for individual variation in response to CHA led to tolerance and failed to manage a prescribed Tb. Starting with a dose (0.25 mg/[kg·h]) and modulating surface temperature to prevent overcooling proved to be an effective means to achieve and maintain Tb between 32°C and 34°C for 24 hours. Increasing surface temperature to 37°C during CHA administration brought Tb back to normothermic levels. All animals treated in this way rewarmed without incident. During the initiation of cooling, we observed bradycardia within 30 minutes of the start of IV infusion, transient hyperglycemia, and a mild hypercapnia; the latter normalized via metabolic compensation. In conclusion, we describe an intravenous delivery protocol for CHA at 0.25 mg/(kg·h) that, when coupled with conductive cooling, achieves and maintains a prescribed and consistent target Tb between 32°C and 34°C for 24 hours.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenosina / Hipotermia Induzida Tipo de estudo: Etiology_studies / Guideline Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenosina / Hipotermia Induzida Tipo de estudo: Etiology_studies / Guideline Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article